UPFRONT Study of Bortezomib-Based Combinations for Elderly Patients with Newly Diagnosed MM


UPFRONT Study of Bortezomib-Based Combinations for Elderly Patients with Newly Diagnosed MM
Slides from a presentation at ASH 2011 and transcribed comments from a recent interview with Paul G Richardson, MD (1/24/12)

Niesvizky R et al. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: Results from all randomized patients in the community-based, phase 3b UPFRONT study. Proc ASH 2011;Abstract 478.

Dr Richardson is Associate Professor of Medicine at Harvard Medical School and Clinical Director of the Jerome Lipper Center for Multiple Myeloma at Dana-Farber Cancer Institute in Boston, Massachusetts.